{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:31:29Z","timestamp":1778254289094,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.dsx.2022.102613","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T22:36:21Z","timestamp":1662762981000},"page":"102613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro- and macrovascular disease"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1647-9031","authenticated-orcid":false,"given":"Michel P.","family":"Hermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evariste","family":"Bouenizabila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Daniel Amoussou-Guenou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jules Gninkoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie A.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel F.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102613_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/17843286.2017.1348710","article-title":"Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive study","volume":"73","author":"Hermans","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.dsx.2022.102613_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102613_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.13973","article-title":"Cardiovascular risk factors in non-alcoholic fatty liver disease","volume":"39","author":"Hagstr\u00f6m","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dsx.2022.102613_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2022.102613_bib5","series-title":"Darren K. McGuire & nikolaus marx","first-page":"181","article-title":"Effect of lipid management on coronary heart disease risk in patients with diabetes. Diabetes in Cardiovascular Disease: a Companion to Braunwald's Heart Disease","author":"Hermans","year":"2015"},{"key":"10.1016\/j.dsx.2022.102613_bib6","series-title":"Kamlakar tripathi","first-page":"481","article-title":"Lipid disorders in diabetes sadikot's textbook of diabetes","author":"Hermans","year":"2019"},{"key":"10.1016\/j.dsx.2022.102613_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4236\/jdm.2020.103013","article-title":"Fatty liver linked to reduced frequency of ocular complications in T2DM","volume":"10","author":"Gninkoun","year":"2020","journal-title":"J\u00a0Diabetes Mellitus"},{"key":"10.1016\/j.dsx.2022.102613_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","article-title":"Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries","volume":"129","author":"Sacks","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2022.102613_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-511X-11-132","article-title":"The atherogenic dyslipidemia ratio [log(TG)\/HDL-C] is associated with residual vascular risk, B-cell function loss and microangiopathy in type 2 diabetes females","volume":"11","author":"Hermans","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2022.102613_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11430859","article-title":"Secondary causes of nonalcoholic fatty liver disease","volume":"5","author":"Kneeman","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dsx.2022.102613_bib11","first-page":"1640","volume":"120","author":"Alberti","year":"2009"},{"key":"10.1016\/j.dsx.2022.102613_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.dsx.2010.05.021","article-title":"Impact of metabolic syndrome on microvascular complications in type 2 diabetes","volume":"4","author":"Hermans","year":"2010","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2022.102613_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.diabet.2010.09.005","article-title":"Statin therapy and cataract in type 2 diabetes","volume":"37","author":"Hermans","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.dsx.2022.102613_bib14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/diabetes.48.9.1779","article-title":"Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes","volume":"48","author":"Hermans","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2022.102613_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsx.2008.02.004","article-title":"Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort","volume":"2","author":"Munoko","year":"2008","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2022.102613_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dsx.2016.08.029","article-title":"Size, density and cholesterol load of HDL predict microangiopathy, coronary artery disease and \u03b2-cell function in men with T2DM","volume":"11","author":"Hermans","year":"2017","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2022.102613_bib17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102613_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102613_bib19","first-page":"413","article-title":"Residual microvascular risk in type 2 diabetes in 2014: is it time for a re-think? A perspective from the Residual Risk Reduction Initiative (R3i)","volume":"5","author":"Hermans","year":"2014","journal-title":"J\u00a0Diabetes Metabol"},{"key":"10.1016\/j.dsx.2022.102613_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108617","article-title":"The role of peroxisome proliferator-activated receptors in healthy and diseased eyes","volume":"208","author":"Escandon","year":"2021","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.dsx.2022.102613_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/dmrr.1075","article-title":"Diabetic cataracts: mechanisms and management","volume":"26","author":"Obrosova","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.dsx.2022.102613_bib22","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.3748\/wjg.v19.i20.3134","article-title":"Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes","volume":"19","author":"Lu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2022.102613_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jdi.12139","article-title":"Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"5","author":"Kim","year":"2014","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.dsx.2022.102613_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdi.12518","article-title":"Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications","volume":"7","author":"Yan","year":"2016","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.dsx.2022.102613_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.dsx.2022.102613_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ebiom.2017.07.008","article-title":"The mechanism of diabetic retinopathy pathogenesis unifying key lipid regulators, sirtuin 1 and liver X receptor","volume":"22","author":"Hammer","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.dsx.2022.102613_bib27","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10620-012-2118-3","article-title":"Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies","volume":"57","author":"Nseir","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dsx.2022.102613_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/950693","article-title":"Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease","volume":"2012","author":"Nakajima","year":"2012","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.dsx.2022.102613_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14390","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy","volume":"38","author":"Marchand","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2022.102613_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","article-title":"Selective peroxisome proliferator-activated receptor alpha modulators (SPPARM\u03b1) in the metabolic syndrome: is pemafibrate light at the end of the tunnel?","volume":"23","author":"Fruchart","year":"2021","journal-title":"Curr Atherosclerosis Rep"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:19:49Z","timestamp":1761729589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1871402122002272"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102613","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro- and macrovascular disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102613"}}